SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gains with arm entering into JVA to incorporate joint venture company in Iran

15 Dec 2016 Evaluate

Cipla is currently trading at Rs. 574.60, up by 6.15 points or 1.08% from its previous closing of Rs. 568.45 on the BSE.

The scrip opened at Rs. 570.00 and has touched a high and low of Rs. 576.00 and Rs. 569.00 respectively. So far 8,281 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 660.00 on 29-Dec-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.

Last one week high and low of the scrip stood at Rs. 585.00 and Rs. 565.00 respectively. The current market cap of the company is Rs. 46,148.00 crore.

The promoters holding in the company stood at 36.74%, while Institutions and Non-Institutions held 35.31% and 26.64% respectively.

Cipla’s wholly owned subsidiary in Netherlands - Cipla Holding B. V. (Cipla Netherlands), has entered into a joint venture agreement (JVA) with Ahran Tejarat Company to incorporate a joint venture company. As per the joint venture agreement, Cipla Netherlands will hold a 75% stake in a joint venture company in Iran while the JV Partner shall hold the remaining 25% stake. 

The total expected investment of Cipla Netherlands in cash in the joint venture company is estimated at being up to a maximum of 16.875 million euro. The joint venture company proposes to undertake manufacturing and marketing of pharmaceutical products in Iran.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.


Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×